These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Secondary amyloidosis in a patient with long duration Crohn's disease treated with infliximab. Fidalgo C; Calado J; Cravo M BioDrugs; 2010 Dec; 24 Suppl 1():15-7. PubMed ID: 21175229 [TBL] [Abstract][Full Text] [Related]
7. Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease. Bell S; Kamm MA Lancet; 2000 Mar; 355(9207):858-60. PubMed ID: 10752696 [No Abstract] [Full Text] [Related]
8. Successful use of maintenance infliximab for nephropathy in a patient with secondary amyloidosis complicating Crohn's disease. Tada Y; Ishihara S; Ito T; Matsui K; Sonoyama H; Oka A; Kusunoki R; Fukuba N; Mishima Y; Oshima N; Moriyama I; Yuki T; Kawashima K; Sato S; Adachi K; Ikeuchi H; Kinoshita Y Intern Med; 2013; 52(17):1899-902. PubMed ID: 23994979 [TBL] [Abstract][Full Text] [Related]
9. Complete remission of nephrotic syndrome secondary to amyloid a amyloidosis in patient with inactive Crohn's disease after treatment by infliximab. Hassani K; Hamzi MA; El Kabbaj D Saudi J Kidney Dis Transpl; 2018; 29(2):456-461. PubMed ID: 29657220 [TBL] [Abstract][Full Text] [Related]
10. Infliximab: how to use it in pediatric Crohn's disease. Ruemmele FM J Pediatr Gastroenterol Nutr; 2004 Jul; 39(1):12-4. PubMed ID: 15187774 [No Abstract] [Full Text] [Related]
11. Discussion on predictors of response to infliximab in patients with Crohn's disease. Hommes D Gastroenterology; 2003 Jun; 124(7):2002-3. PubMed ID: 12812196 [No Abstract] [Full Text] [Related]
12. Anti-TNF therapy for Crohn's disease: a perspective (infliximab is not the drug we have been waiting for). Shanahan F Inflamm Bowel Dis; 2000 May; 6(2):137-9. PubMed ID: 10833074 [No Abstract] [Full Text] [Related]
13. Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn's disease. Izbéki F; Nagy F; Szepes Z; Kiss I; Lonovics J; Molnár T Inflamm Bowel Dis; 2008 Mar; 14(3):429-31. PubMed ID: 17973302 [No Abstract] [Full Text] [Related]
14. [Management and treatment of Crohn's disease. 2. Anti-cytokine therapy]. Ito H Nihon Naika Gakkai Zasshi; 2009 Jan; 98(1):88-93. PubMed ID: 19338091 [No Abstract] [Full Text] [Related]
15. Reactive hepatitis in a patient with Crohn's disease successfully treated with infliximab: does tumor necrosis factor alpha play a role in reactive hepatitis? Magro F; Pereira P; Carneiro F; Veloso FT Inflamm Bowel Dis; 2005 Jan; 11(1):88-90. PubMed ID: 15674127 [No Abstract] [Full Text] [Related]
17. Infiximab for treatment of systemic amyloidosis associated with Crohn's disease. Said Y; Debbeche R; Hamzaoui L; Lounissi M; Trabelsi S; Bouzaidi S; Salem M; Abdelmoula L; Najjar T J Crohns Colitis; 2011 Apr; 5(2):171-2. PubMed ID: 21453891 [No Abstract] [Full Text] [Related]
18. Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception. Angelucci E; Cocco A; Viscido A; Caprilli R Inflamm Bowel Dis; 2008 Mar; 14(3):435-6. PubMed ID: 18050300 [No Abstract] [Full Text] [Related]
19. Infliximab (Remicade), a new biological treatment for Crohn's disease. D'Haens GR Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573 [TBL] [Abstract][Full Text] [Related]
20. Infliximab treatment induces levels of the active azathioprine metabolite TGTP in Crohn's disease. Teichgräber U; Atreya I; Atreya R; Schwab M; Neurath MF Inflamm Bowel Dis; 2013; 19(4):E54-5. PubMed ID: 22532373 [No Abstract] [Full Text] [Related] [Next] [New Search]